NCT03412058 - Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists | Biotech Hunter

Enrollment

670

Participants

Timeline

Start Date

June 27, 2018

Primary Completion Date

January 2, 2024

Study Completion Date

December 31, 2025

Conditions

MelanomaNon Small Cell Lung CancerHead and Neck Squamous Cell Carcinoma

Interventions

PROCEDURE

Biopsy

To be performed prior to anti-PD1/PD-L1 treatment initiation

PROCEDURE

Biopsy

To be performed after 42 (±3) days of anti-PD1 or PD-L1 treatment in consenting patients

PROCEDURE

Biopsy

To be performed at disease progression if medically feasible

Trial Locations (19)

63011

Centre Jean Perrin, Clermont-Ferrand

Unknown

Institut Bergonie, Bordeaux

Centre Hospitalier de Caen, Caen

Centre Hospitalier Inter. de Creteil, Créteil

Centre Georges François Leclerc, Dijon

Centre Oscar lambret, Lille

Centre Léon Bérard, Lyon

Institut Régional du Cancer de Montpellier, Montpellier

Institut de cancérologie de l'ouest, Nantes

Centre Antoine Lacassagne, Nice

Institut Curie, Paris

Institut Jean Godinot, Reims

Centre Eugène Marquis, Rennes

Institut Curie - Hôpital René Huguenin, Saint-Cloud

CHU Saint-Etienne, Hôpital Nord, Saint-Etienne

Institut Claudius Regaud - IUCT- 0, Toulouse

CHU de Tours, Tours

Institut Cancérologie de Lorraine, Vandœuvre-lès-Nancy

Gustave Roussy, Villejuif

All Listed Sponsors

collaborator

Fondation ARC

OTHER

lead

UNICANCER

OTHER